We now seek comments on a draft incretin therapies summary position and prescribing guidance. It includes guidance on use in type 2 diabetes, weight management, cardiovascular disease secondary prevention, and use in combination with insulin.
This consultation will run for six weeks and close at 5pm on Friday 31st July 2026. To take part, visit the consultations page.